FDA approves first generic Epipen

The FDA this week approved the first generic version of Mylan‘s (NSDQ:MYL) Epipen emergency allergy auto-injector. Teva Pharmaceuticals (NYSE:TEVA), which won the historic approval, plans to market the generic epinephrine auto-injector in 0.3mg and 0.15mg doses. There are other epinephrine auto-injectors on the market in the U.S., but Teva’s is the first that’s approved to directly substitute

Lessons learned: How Jeff Karp stays at the forefront of innovation

Serial entrepreneur Jeff Karp has a philosophy for his laboratory: find important problems and get solutions to people quickly. To learn about the exciting technologies emerging from Karp’s lab, join us at DeviceTalks Boston on Oct. 8-10. After Jeff finished his PhD in chemical and biomedical engineering at the University of Toronto, he knew he wanted

How Insulet’s CEO plans to create a billion-dollar business

When Pat Sullivan joined Insulet (NSDQ:PODD) in 2014, the Billerica, Mass.-based company was reeling in roughly $300 million in revenue selling its Omnipod tubless insulin delivery system. Sullivan, a veteran of the medtech industry, saw a path to creating a billion-dollar company and it centered around the concept of making life easier for people with diabetes. “I

Drug delivery systems: Turning active medical devices into transformative solutions

C&K Cutting Edge Blog #1 By Roger Bohannan – C&K Medical Segment Leader Diabetes is the fastest growing disease among the top 10 most lethal conditions in the human population. The diabetes patient population has grown to 420 million people over the past 15 years, according to the World Health Organization, and is slated to

BioEclipse looks to synergistic therapies to topple stubborn cancers

For the last 20 years, Pamela Contag has studied cancer. And in that time, the world’s understanding of cancer has changed dramatically. “I remember when people were saying ‘One gene, one protein,” which we now know is wrong,” she told Drug Delivery Business News. “And then we thought cancer was a disruption in proliferation and really

Researchers use microparticles for targeted delivery of brain cancer therapy

A team of researchers from Brigham & Women’s Hospital, Mass. Institute of Technology and Mass. General Hospital demonstrated that localizing the delivery of NAMPT inhibitors can extend survival in a mouse model of glioma, according to a paper published this week in the Proceedings of the National Academy of Sciences. The scientists created a test to check for a mutation linked

Tackling drug delivery challenges with TissueGen’s implantable fibers

TissueGen‘s chief scientist and co-founder, Kevin Nelson, told Drug Delivery Business News the story behind the company he founded in 2000 and its drug delivery technology, the Elute fiber.  DDBN: How did TissueGen get its start? Nelson: In 1996, while faculty in biomedical engineering at The University of Texas at Arlington, I was working with

Novo Nordisk exec: In the digital age, it’s not enough to have a better molecule

Much of Dr. Todd Hobbs’ life has centered around diabetes – he was diagnosed with Type I diabetes roughly 30 years ago and now he is the father of a child with diabetes. At his Kentucky-based primary care practice, he took on diabetic patients and helped manage their care. And when he made the jump

Gerresheimer to acquire Sensile Medical and its drug-delivery tech

Gerresheimer plans to acquire Swiss medical technology company Sensile Medical and its array of liquid drug delivery devices. The buyout is a perfect fit in Gerresheimer’s portfolio, the company explained, since it will boost Gerresheimer’s drug delivery offerings and add new digital and electronic capabilities into the mix. Get the full story at our sister site, Drug Delivery

This wireless system powers devices inside the body

Massachusetts Institute of Technology researchers and Brigham and Women’s Hospital scientists have developed a wireless, ingestible system that can power and communicate with devices that are implanted deep within the body. The researchers suggest that the system could be used to deliver drugs, monitor conditions inside the body or treat diseases by stimulating the brain

Data Sciences International launches inhalation exposure system

Data Sciences International, a subsidiary of Harvard Bioscience, recently launched a new inhalation and exposure system called the DSI Buxco Inhalation Exposure System. The new inhalation exposure system is designed for ease-of-use for researchers while also giving them flexibility. It features remote sensors and hardware control system that are linked by a microprocessor-based feedback loop.

Sanford Health and Freudenberg Medical partner on infusion systems

Sanford Health (Sioux Falls, S.D.) and Freudenberg Medical (Carpinteria, Calif.) announced that they have entered a joint research and development agreement to develop infusion systems to treat blood clots and blockages in blood vessels. A catheter used in the infusion systems was designed by vascular surgeon Dr. Patrick Kelly at Sanford Health Innovations, a part of

Noble aims to put patients at ease with auto-injector training devices

In the early days of auto-injectors, people learned how to use their devices by practicing with the skin of an orange, according to Noble‘s research manager, Joe Reynolds. “The rationale was ‘Well, let’s teach patients how to penetrate a skin-like membrane into a soft tissue to replicate what the human body would be like,’” he […]

Beta Bionics taps Senseonics’ implantable glucose monitor for artificial pancreas

Senseonics‘ (NYSE:SENS) said today that it inked a deal to integrate glucose data from its Eversense continuous glucose monitoring system into Beta Bionics‘ investigational iLet bionic pancreas. According to the terms of the development agreement, Beta Bionics and Senseonics will work together to combine the two systems in the hopes of driving insulin and glucagon dosing […]

Medtech veteran Mir Imran wants to replace injections with the ‘robotic pill’

Companies have tried for decades to deliver protein-based drugs orally. Can Mir Imran and his company’s robotic pill succeed where so many have failed? Mir Imran has been building medical device companies for 40 years. Perhaps known best for his work on the first FDA-approved implantable cardioverter defibrillator, Imran’s model is to identify big, unsolved